Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.9
-46.40%
40%
—
-3.34%
80%
—
5 Years
Score4.9
Net Growth-46.40%
Net Trend40%
Net Income Consistency—
Rev Growth-3.34%
Rev Trend80%
Revenue Consistency—
Regeneron Pharmaceuticals Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 66M to $ 14.34B and net income went from -$ 95M to $ 4.50B. Revenue increased in 18 of those 20 years; net income in 11.
Between 1995 and 2025, revenue grew from $ 27M to $ 14.34B and net income went from -$ 23M to $ 4.50B. Revenue increased in 24 of those 30 years; net income in 15.
Regeneron Pharmaceuticals Inc currently holds a 20-year HDB Score of 7.8 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 797.99 | — |
1 Year2025-08-12 | $ 553.52 | 44.17% |
5 Years2021-08-12 | $ 603.02 | 32.33% |
10 Years2016-08-12 | $ 418.09 | 90.87% |
20 Years2006-08-11 | $ 13.80 | 57x |
30 Years1996-08-12 | $ 16.98 | 46x |
All Time1991-04-02 | $ 20.95 | 38x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | 30 Years1996-08-12 | All Time1991-04-02 |
|---|---|---|---|---|---|---|---|
| Price | $ 797.99 | $ 553.52 | $ 603.02 | $ 418.09 | $ 13.80 | $ 16.98 | $ 20.95 |
| Return | — | 44.17% | 32.33% | 90.87% | 57x | 46x | 38x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 15.53B | $ 4.32B | |
| 2025 | $ 14.34B | $ 4.50B | $ 8.60B |
| 2024 | $ 14.20B | $ 4.41B | $ 9.01B |
| 2023 | $ 13.11B | $ 3.95B | $ 10.84B |
| 2022 | $ 12.17B | $ 4.33B | $ 7.74B |
| 2021 | $ 16.07B | $ 8.07B | $ 5.69B |
| 2020 | $ 8.49B | $ 3.51B | $ 6.72B |
| 2019 | $ 7.86B | $ 2.11B | $ 3.21B |
| 2018 | $ 6.71B | $ 2.44B | $ 4.56B |
| 2017 | $ 5.87B | $ 1.19B | $ 2.89B |
| 2016 | $ 4.86B | $ 895M | $ 1.03B |
| 2015 | $ 4.10B | $ 636M | $ 1.67B |
| 2014 | $ 2.81B | $ 348M | $ 1.36B |
| 2013 | $ 2.10B | $ 424M | $ 693M |
| 2012 | $ 1.37B | $ 750M | $ 308M |
| 2011 | $ 445M | -$ 221M | $ 526M |
| 2010 | $ 459M | -$ 104M | $ 249M |
| 2009 | $ 379M | -$ 67M | $ 341M |
| 2008 | $ 238M | -$ 82M | $ 474M |
| 2007 | $ 125M | -$ 105M | $ 766M |
| 2006 | $ 63M | -$ 102M | $ 459M |
| 2005 | $ 66M | -$ 95M | $ 298M |
| 2004 | $ 174M | $ 41M | $ 295M |
| 2003 | $ 57M | -$ 107M | $ 293M |
| 2002 | $ 21M | -$ 124M | $ 264M |
| 2001 | $ 21M | -$ 76M | $ 385M |
| 2000 | $ 59M | -$ 23M | $ 117M |
| 1999 | $ 34M | -$ 23M | $ 66M |
| 1998 | $ 38M | -$ 8M | $ 19M |
| 1997 | $ 33M | -$ 11M | $ 28M |
| 1996 | $ 24M | -$ 32M | $ 34M |
| 1995 | $ 27M | -$ 23M | $ 32M |
| 1994 | $ 23M | -$ 30M | $ 23M |
| 1993 | $ 10M | -$ 39M | $ 12M |
| 1992 | $ 11M | -$ 19M | $ 16M |
| IPO1991 | $ 7M | -$ 4M | $ 26M |
Explore beyond REGN
You're looking at Regeneron Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
